This is a randomized, double-blind, multi-center study to assess the safety and effectiveness
of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily
subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation
in patients with Hodgkin's or non-Hodgkin's lymphoma.